BCRX Q2 2019 Earnings — BioCryst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

BCRXBioCryst Pharmaceuticals, Inc.

$2B

Q2 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-88.4% YoY

Gross Profit

$1M98.2% margin

Operating Income

-$35M-2411.5% margin

Net Income

-$38M-2598.7% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

-75.4%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$116M

Total Liabilities

$126M

Stockholders' Equity

-$9M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$12M	-88.4%
Gross Profit	$1M	$12M	-88.4%
Operating Income	-$35M	-$18M	-91.3%
Net Income	-$38M	-$18M	-104.0%

Revenue Segments

Collaborative and Other Research and Development

$752,00052%

Royalty

$696,00048%